NORITATE (metronidazole) by Bausch + Lomb. Approved for nitroimidazole antimicrobial [epc]. First approved in 1997.
Drug data last refreshed 3h ago · AI intelligence enriched 1w ago
NORITATE is a topical metronidazole cream approved in 1997 for treatment of rosacea and other dermatological conditions caused by anaerobic bacteria and parasites. Metronidazole is a nitroimidazole antimicrobial that disrupts bacterial DNA, making it effective for localized skin infections. The product is applied directly to affected skin areas for targeted therapeutic delivery.
Declining topical antimicrobial market with modest $3M spending signals a mature product with reduced commercial staffing and focus on managed care efficiency.
Nitroimidazole Antimicrobial
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Chlorhexidine and/or Metronidazole Plus FB301 Pre-treatment Trial
A Single-center, Open-label, Study Evaluating Safety and Pharmacokinetics of Single Doses of Zidebactam-Cefepime and Metronidazole Alone or in Combination.
Effectivity and Safety of Metronidazole 1% Cream in Rosacea Therapy
Personalized AZithromycin/metronidAZole Therapy in Pediatric Crohn's Disease (CD)
Ceftolozane/Tazobactam (MK-7625A) Plus Metronidazole Versus Meropenem for Participants With Complicated Intra-abdominal Infection (MK-7625A-015)
Worked on NORITATE at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moPositions linked to NORITATE are rare (0 identified jobs), reflecting the product's mature, declining lifecycle and minimal commercial growth ambitions. Working on this product favors operational, regulatory, and cost-management expertise over traditional commercial development roles.